Perrigo Company / Omega Pharma Invest merger inquiry

The CMA investigated the anticipated acquisition by Perrigo Company plc of Omega Pharma Invest NV.

Statutory timetable

Phase 1 date Action
9 April 2015 Decision published
9 March 2015 Decision announced
13 January 2015 to 26 January 2015 Invitation to comment
13 January 2015 Launch of merger inquiry

Phase 1

CMA clearance decision

9 March 2015: The CMA has cleared the anticipated acquisition by Perrigo Company plc of Omega Pharma Invest NV. The full text of the decision is available below.

Launch of merger inquiry

13 January 2015: The CMA announced the launch of its merger inquiry by notice to the parties.

Invitation to comment: Now closed

13 January 2015: The CMA is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

Contact

Please send written representations about any competition or public interest to:

Ronan Scanlan
Competition and Markets Authority
Victoria House
Southampton Row
London
WC1B 4AD

Ronan.Scanlan@cma.gsi.gov.uk

Updates to this page

Published 13 January 2015
Last updated 9 April 2015 + show all updates
  1. Full text of the decision published.

  2. First published.